2022 Olympics: Russian skater Kamila Valieva can compete in Beijing despite drug test, sports court rules

Kamila Valieva
(Image credit: Christine Poujoulat/AFP/Getty Images)

Russian figure skater Kamila Valieva can compete in the individual women's skating events at the Beijing Olympics despite her positive pre-Games drug test, the Court of Arbitration for Sport ruled Monday. The CAS said it decided against barring Valieva from competition because she is, at 15, a "protected person" under the World Anti-Doping Code, her drug tests in Beijing have been clean, and there are "serious issues of untimely notification" in the results of her Dec. 25 drug test, returned by the Swedish lab on Feb. 8.

"The panel considered that preventing the athlete to compete at the Olympics would cause her irreparable harm in the circumstances," CAS Director General Matthieu Reeb said. The panel did not rule on the merits of Valieva's case or whether she will get to keep any medals she wins, including the gold won by not yet awarded to the Russian Olympic Committee for the team skating event. Valieva is favored to win the gold in the individual competition.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.